CATALYST PHARMACEUTICALS, INC. 8-K/A

What Happened
Catalyst Pharmaceuticals, Inc. (CPRX) reported in an 8-K filed March 19, 2026 that the U.S. District Court for the District of New Jersey entered an order on March 18, 2026 postponing the start of the bench trial against Hetero USA, Inc. The trial — which concerns the validity of Catalyst’s Orange Book‑listed patents covering FIRDAPSE® — was moved from March 23, 2026 to May 18, 2026. The patents at issue have listed expiration years of 2032, 2034 and 2037.

Key Details

• Court order date: March 18, 2026; 8-K filed by Catalyst on March 19, 2026.
• Original trial start: March 23, 2026; new start date: May 18, 2026.
• Parties: Catalyst Pharmaceuticals vs. Hetero USA, Inc.
• Subject: Validity of Orange Book‑listed patents for FIRDAPSE® (patents expire in 2032, 2034, 2037).

Why It Matters
This is a procedural delay in a high‑stakes patent validity trial that affects the timeline for resolving challenges to Catalyst’s FIRDAPSE patent protection. For investors, the new trial date pushes back the schedule for a court decision that could influence future competition and the timing of potential generic entry tied to those Orange Book patents. The filing contains no new financial guidance or outcome prediction — it only reports the court’s rescheduling.